The obesity field’s favorite pairing has been an injection: a GLP-1 drug plus an amylin drug, the logic behind Novo Nordisk’s investigational CagriSema and a growing list of rivals. Ascletis Pharma wants to put the same idea in a tablet.
On November 11, the Hong Kong-listed company announced that it had submitted an investigational new drug application to the U.S. Food and Drug Administration for ASC30_39 FDC, a once-daily oral fixed-dose combination of two small molecules: ASC30, a GLP-1 receptor agonist, and ASC39, a selective amylin receptor agonist.
Ascletis describes it as the first co-formulation of an oral GLP-1 receptor agonist and an oral amylin receptor agonist to reach the IND submission stage. That first-in-class description is the company’s claim, rather than an independently established regulatory designation.
The application is a meaningful development milestone. It is not evidence that the combination works in people. The publicly disclosed pharmacokinetic results for the combination tablet come from dogs, and the weight-loss results for the amylin component come from rats.
ASC30 has already advanced to large human trials on its own. But ASC30_39, the two-drug tablet, has no reported human efficacy or safety results.
The combination is moving toward human testing. It has not demonstrated human weight loss.
What Ascletis Filed With the FDA
An IND is an application that allows a developer to begin clinical investigation of an experimental medicine, subject to FDA requirements. It is not an application for permission to market the drug.
Under the usual U.S. process, an IND can take effect 30 days after the FDA receives it unless the agency places the proposed investigation on clinical hold. The FDA can also notify a sponsor that studies may begin earlier.
Ascletis says its application is supported by preclinical results and formulation development work. The company reports that ASC30 and ASC39 can be combined in a relatively small tablet with room-temperature stability and acceptable compatibility between the ingredients.
The central disclosed combination study was conducted in dogs.
According to Ascletis, orally administered ASC30_39 tablets produced favorable bioavailability, drug exposure and a half-life of up to 12 hours. In a head-to-head dog study, the pharmacokinetic characteristics were consistent with those observed when the two ingredients were administered separately.
That is useful formulation evidence. If one molecule interferes with the absorption or exposure of another when both are placed in the same pill, a fixed-dose combination can become difficult to develop.
Ascletis says it did not observe that problem in its dog comparison.
But the company has not disclosed a detailed human pharmacokinetic profile for the combined tablet. The 12-hour figure is from dogs, not patients, and it cannot be assumed to predict the same duration in people.
The company also has not presented human weight-loss results or a human safety dataset for ASC30_39.
Importantly, the dog results were not newly generated for the November filing announcement. Ascletis had already described them in an April 7, 2026, filing to the Hong Kong Stock Exchange.
November’s development was the IND submission itself.
The dog study suggests the two ingredients can be delivered together. It does not show that the combination treats obesity in humans.
Why GLP-1 Plus Amylin Matters to Ascletis
GLP-1 receptor agonists help regulate appetite, food intake and glucose metabolism. Amylin, a hormone normally released alongside insulin, contributes to feelings of fullness and the regulation of food intake through overlapping but distinct biological pathways.
Combining the two mechanisms is an attractive strategy because developers hope it can improve weight-loss efficacy beyond what either pathway delivers on its own.
Novo Nordisk is pursuing that logic with CagriSema, an investigational once-weekly injection combining semaglutide and the amylin analog cagrilintide. Other developers, including Eli Lilly, are advancing amylin-based programs.
Most established GLP-1 and amylin combination approaches involve injectable peptides. Ascletis is taking a different chemical route.
ASC30 and ASC39 are small molecules, not peptide drugs. They are designed to activate receptors normally targeted by peptide hormones, but their chemical structures and formulation requirements differ from those of conventional therapeutic peptides.
The ambition is to offer both receptor activities in a single tablet taken once a day.
For patients, an effective oral combination could offer an alternative to injections. For manufacturers, it would establish another way to compete in a market increasingly divided between weekly injectable drugs and daily oral therapies.
Convenience, however, is not sufficient evidence of clinical value. A combined pill would still need to demonstrate meaningful weight reduction, acceptable tolerability and a practical dosing schedule.
Ascletis is not the only developer pursuing the amylin pathway. Grey Pepper previously examined Eccogene’s small-molecule amylin program and Lilly’s eloralintide development program, two different approaches to testing the clinical value of amylin receptor agonism.
ASC30 Is Much Further Along Than ASC39
The two components of ASC30_39 are at very different stages of development.
ASC30, the oral GLP-1 receptor agonist, is already undergoing evaluation in two large global Phase 3 trials, AURORA-1 and AURORA-2.
The program is expected to enroll approximately 4,600 participants with obesity or overweight across the United States, Europe and Canada.
AURORA-1 studies people without type 2 diabetes, while AURORA-2 studies those with type 2 diabetes. Both evaluate once-daily ASC30 at maintenance doses of 20 mg, 40 mg and 60 mg over 72 weeks, with dose-escalation periods.
Ascletis expects topline Phase 3 results in the third quarter of 2028. Those are company projections, not completed clinical outcomes.
The company has also promoted ASC30’s gastrointestinal tolerability. It previously claimed approximately half the vomiting rate reported with Lilly’s oral GLP-1 drug orforglipron when both medicines used weekly dose escalation.
That comparison deserves caution. It was drawn from separate, non-head-to-head clinical studies, not from participants randomly assigned to ASC30 or orforglipron in the same trial.
Differences in participant characteristics, dose escalation and adverse-event reporting can distort cross-trial comparisons.
The claim therefore does not establish that ASC30 causes less vomiting than orforglipron under equivalent conditions.
Orforglipron has already moved beyond that stage: the FDA approved it in April 2026 under the brand name Foundayo for chronic weight management in eligible adults.
That makes ASC30’s eventual Phase 3 efficacy and tolerability results especially important for judging whether it can compete with an approved oral small-molecule GLP-1 therapy.
ASC39, by contrast, remains much earlier in development.
The Amylin Half Has Only Early Preclinical Efficacy Data
Ascletis submitted a separate IND for ASC39 in October 2026 and said it anticipated beginning a Phase 1 study in the fourth quarter.
ASC39 is a selective amylin receptor agonist designed to favor the human amylin 1 receptor over the human calcitonin receptor.
In a laboratory receptor-activation assay, Ascletis reported approximately 40-fold selectivity for the human amylin 1 receptor over the calcitonin receptor.
The company compared that finding with the investigational amylin peptide eloralintide, which showed approximately 64-fold selectivity in the same assay.
Those numbers describe receptor activity measured under laboratory conditions. They do not establish how selective either medicine will be in the human body, or whether the difference will translate into better weight loss or fewer adverse effects.
Ascletis also reported a short animal efficacy study in diet-induced obese rats.
Once-daily oral ASC39, given for six consecutive days at 5 mg/kg, produced a 6.6% placebo-adjusted reduction in body weight. The company reported a 5.6% reduction for eloralintide in its preclinical comparison.
These are rodent results, not estimates of human weight loss. They cannot be compared directly with the percentages reported from large human obesity trials.
The six-day treatment period is also too short to establish long-term efficacy, durability of weight loss or chronic safety.
Ascletis chief executive Jinzi Jason Wu has suggested that selectivity for the amylin receptor could be important for both efficacy and tolerability.
That remains a development hypothesis. Human trials will need to establish whether the proposed pharmacological advantages translate into clinical benefits.
A six-day rat study is a reason to investigate further. It is not evidence that a daily amylin pill works in people.
The Missing Data and the Missed Timeline
Ascletis’s November announcement provides an outline of the combination program, but it leaves several important questions unanswered.
First, the company has not publicly reported human pharmacokinetic, efficacy or safety data for ASC30_39.
Second, the disclosed combination pharmacokinetic results do not include enough numerical detail to independently assess variability in drug exposure, or how consistently the tablet delivers both ingredients.
Third, the company’s announcement does not provide a complete first-in-human trial protocol, including participant numbers, selected dose levels and the proposed duration of treatment.
Those details matter because the two ingredients could behave differently when administered together in people, even if their pharmacokinetics were compatible in dogs.
There are also safety questions that a short animal program cannot resolve. Both GLP-1 and amylin receptor agonism can affect appetite and gastrointestinal function. Combining the pathways could alter tolerability, which is one reason early human dose-escalation studies will be important.
The program also missed an earlier stated filing target.
In an April 7 announcement, Ascletis said it expected to submit the ASC30_39 IND during the third quarter of 2026. The application was instead submitted on November 11, after that window had closed.
The company has not established in its November announcement why the target changed. The later submission date is documented; attributing it to a specific scientific, manufacturing or regulatory problem would be speculation.
For investors and researchers, the more useful milestone will be the first disclosed human data rather than the exact date the application entered the regulatory system.
What Happens Next for Ascletis’s Oral GLP-1 and Amylin Pill
There are three separate clinical developments to watch.
The first is whether the ASC30_39 IND becomes effective without a clinical hold and Ascletis announces a first-in-human study of the combined tablet.
The second is ASC39’s planned Phase 1 study. Initial human testing of the amylin component should help clarify its safety, tolerability and pharmacokinetic characteristics before the combination can be evaluated more extensively.
The third is the ASC30 Phase 3 program, with topline results projected for the third quarter of 2028.
Those findings will help determine whether the GLP-1 component is competitive with existing oral drugs, including orforglipron.
The combined pill will ultimately have a harder question to answer: does adding ASC39 produce sufficiently greater clinical benefit to justify the complexity and potential additional adverse effects of using two active molecules?
That requires controlled human evidence comparing the combination against its components, or another scientifically appropriate treatment comparator.
Ascletis has a clear commercial thesis. Once-daily oral treatment targeting two complementary hormone pathways could become a convenient alternative to injectable combination therapies.
The evidence does not yet demonstrate that the approach works.
The dog study suggests the formulation can deliver both small molecules together. The rat study indicates that ASC39 has biological activity worth investigating. And the IND submission shows that Ascletis is seeking to move the combined formulation into human development.
Those are three different achievements, each with its own limits.
Ascletis has filed the paperwork for an idea. Human data will decide whether it becomes a medicine.
Sources
- Ascletis Pharma / Hong Kong Stock Exchange — IND Submission for ASC30_39 FDC, November 11, 2026.
- Ascletis Pharma / PR Newswire — ASC30_39 IND Submission and Preclinical Summary, November 11, 2026.
- Ascletis Pharma — IND Submission for Oral ASC39, October 25, 2026.
- Ascletis Pharma — First Participant Dosed in ASC30 Global Phase 3 Program, August 30, 2026.
- Ascletis Pharma / Hong Kong Stock Exchange — Selection of ASC30_39 Combination for Clinical Development, April 7, 2026.
- U.S. Food and Drug Administration — IND Application Procedures: Overview.
- U.S. Food and Drug Administration — Approval of Foundayo (orforglipron), April 1, 2026.
- Novo Nordisk — CagriSema Development and ObesityWeek 2026 Program.
